Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), announced the appointment of Natalia Breyner, PhD in Immunology, as Project Manager – Research & Development.
Physiogenex appoints Dr. Natalia Breyner as Project Manager
Natalia will bring her strong expertise in 3D cell and organoids culture, gut-brain axis and microbiome and her robust experience in managing in vivo efficacy studies for drug targeting metabolic diseases. One of her missions is to develop new in vitro technologies and cell systems to model metabolic disorders dedicated to drug screening and efficacy evaluation.
Physiogenex is a leading preclinical research organization providing non-clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.